Patients suffering from CHD or CV disorder. Rehydrate patients w/ considerable dehydration prior to starting therapy. Consider possibility of fluid retention, oedema or HTN in patients w/ preexisting oedema, HTN or heart failure. Do not discontinue antiplatelet therapy if etoricoxib treatment is ongoing; if indicated, consider in patients at risk for or w/ a history of CV or other thrombotic effects. Patients w/ history of ischemic heart disease. GI ulcers/ulcer complications may occur; who are at higher risk for perforation, ulcers & bleeding eg, w/ prior history of GI perforation, ulcers & bleeding, & patients >65 yr. Previous acute asthmatic attacks, urticaria, or rhinitis precipitated by salicylates or non-selective COX inhibitors. May mask fever, which is a sign of infection. Not recommended in patients w/ advanced renal disease; closely monitor renal function if therapy must be initiated. Patients w/ pre-existing severe renal function impairment, uncompensated heart failure or cirrhosis; consider monitoring of renal function or discontinue if needed. Elevations of alanine &/or aspartate aminotransferase (approx 3 times the upper limit of normal). Signs & symptoms of liver dysfunction, abnormal liver function tests. Avoid use during late pregnancy. Lactation. Childn.
Manage Account
Change Password
Sign Out
